African Americans may be less responsive to asthma treatment and more likely to die from the condition, in part, because they have a unique type of airway inflammation, according to a study led by researchers at the University of Illinois at Chicago College of Medicine

Airway inflammation is a key component of asthma, and innovations in treatment are becoming more personalized based on the specific type of airway inflammation in a patient, says Dr. Sharmilee Nyenhuis, assistant professor of medicine at UIC and corresponding author on the study. "Emerging evidence suggests that differences in airway inflammation can affect a patient's response to treatment, but whether the patterns of airway inflammation vary across race has, until now, been very unclear," said Nyenhuis, of UIC's division of pulmonary, critical care, sleep and allergy. Black men and women are two to three times more likely than whites to be hospitalized or die from asthma. And while many factors contribute to the burden of asthma in African Americans — such as access to health care and environmental exposures — rates are disproportionate even when social and environmental elements are taken into account. Nyenhuis and her colleagues performed a secondary analysis of more than 1,000 sputum samples obtained from AsthmaNet, a nationwide clinical research network created by the National Heart Lung and Blood Institute, and the Asthma Clinical Research Network. Samples of the coughed-up fluids were from past clinical trial participants over the age of 12 with mild or moderate persistent asthma and who had not smoked within the last year. The samples were tested for the presence of eosinophils — a type of white blood cell. The study is one of the largest and most diverse trials conducted in the United States on race and asthma, with 26% of the patients self-identifying as African American. Researchers found that black patients were more likely to exhibit eosinophilic airway inflammation than whites, despite taking comparable doses of asthma medication, such as inhaled corticosteroids. "Our findings of higher numbers of African Americans with this type of airway inflammatory pattern suggests a mechanism that may account for more severe and difficult to control asthma in African Americans," said Nyenhuis. "It follows that the persistence of eosinophilic airway inflammation in African Americans may be associated with asthma exacerbations and an impaired response to corticosteroids." The findings suggest that black patients with eosinophilic airway inflammation may not benefit from increasingly strong corticosteroid treatment — instead, other targeted therapies may need to be considered and researched as a treatment option for those black patients with difficult to control eosinophilic asthma.